What's new in hypochromy.
Hypochromy is a common dermatological disorder. However, its treatment still gives unsatisfactory results. Interesting clues into the understanding of the pathophysiology of hypochromy have been recently brought about thanks to the pigmentary side effects reported with the new tyrosine kinase inhibition treatments. New therapeutic approaches to hypochromy are further discussed.
Passeron
Thierry
T
Department of Dermatology, Hôpital de l'Archet 2, Nice, France. t.passeron@free.fr
Ortonne
Jean-Paul
JP
D000279:Administration, Cutaneous; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D028022:Low-Level Light Therapy; D010789:Phototherapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014820:Vitiligo / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
D000975:Antioxidants; D065095:Calcineurin Inhibitors; D007641:Keratolytic Agents; C055085:calcipotriene; D011505:Protein-Tyrosine Kinases; D002117:Calcitriol; D016559:Tacrolimus